Nephrological aspects ofblood diseases


Cite item

Full Text

About the authors

L S Biryukova

V S Timokhov

References

  1. Городецкий В. А., Горелов В. Г., Иосад В. М. и др. Интенсивная терапия критических состояний в гематологической клинике. Тер. арх.1988; 60 (5): 118-124.
  2. Савченко В. Г. Современная стратегия терапии острых миелоидных лейкозов взрослых: Дис. ... д-ра мед. наук. 1993.
  3. Шаманский С. В., Белоусов Е. А., Буря А. Е., Потехин Н. П. Почечная недостаточность у онкогематологических больных в отделении интенсивной терапии. В кн.: Всероссийская науч.-практ. конф. с международным участием "Проблемы раннего постиитостатического периода". М.: 2002 .
  4. Ashkenazi У. J., Kramer В. S., Barman E. Short-term outcome among patients with leukemia and lymphoma admitted to a medical intensive care unit. South. Med. J. 1986:79: 1086-1088.
  5. Brunet F., Lanore J. J., Dhainaut J. F. et al. Is intensive care justified for patients with hematological malignancies? Intens. CareTher, 1990; 16:.291-297.
  6. Cella D. F., Orav E. J., Kornblith A. B. et al. Socioeconomic status and cancer survival. J. Clin. Oncol. 1991; 9 (8): 1500- 1509.
  7. Мухин Н. А., Тареева И. Е., Шилов Е. M. Клиника и диагностика заболеваний почек. М.: Гэотар-Мед; 2002.
  8. Тареев Е. М. Клиническая нефрология. М.: Медицина; 1983.
  9. Воробьев А. И. Руководство по гематологии. М.: Медицина; 1985.
  10. Файнштейн Ф. Э., Козинец Г. И., Бахрамов С. М., Хохлова М. П. Болезни системы крови. М.: Медицина; 1980.
  11. Hande К. R., Noone R. M., Stone W. I. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am. J. Med. 1984; 76: 47-56.
  12. Leach At., Parsons R. M., Reilly J. Т., Winfield D. A. Efficacy of urate oxidase (uricozyme) in tumor lysis induced urate nephropathy. Clin. Lab. Haematol. 1998; 20 (3): 169-172.
  13. Netea M. G., Kullberg B. J., Blok W. L. et al. The role of hyperuricemia in the increased cytokine production after lipopolysaccharide challenge inneutropenic mice. Blood 1997; 89 (2): 577-582.
  14. Simmonds H. A., Cameron J. S., Morris G. S. et al. Purine metabolites in uremia. In: Ringoir S., ed. Uremic toxins. New- York: Plenum Press; 1987.
  15. Singler L. J. Renal and urological complication of hemophilia.In: Brinkhaus К. М., ed. Handbook of hemophilia. Amsterdam: Excerpta medica;1975. 377-388.
  16. Bacon J. M., Young I. F. ABO incompatible blood transfusion. Pathology. 1989; 21 (3): 181-184.
  17. Le Pennec P. Y., Tissier A. M., Mannessier L. et al. Immunohemolytic transfusion reactions. Report of 61 cases. Transfus. Clin. Biol. 1996; 3 (3): 157-165.
  18. Lieberthal W., Wolf E. F., Rennke H. G. et al. Renal ischemia and reperfusion impair endothelium-dependent vascular relaxation. Am. J. Physiol. 1989; 256: P894-P900.
  19. McClelland D. В., Phillips P. Errors in blood transfusion in Britain: survey of hospital hematology departments. Br. Med. J. 1994; 308 (6938): 1205-1206.
  20. Molitoris B. A. New insight into the cell biology of ischemic acute renal failure. J. Am. Soc. Nephrol. 1991; 1: 1263-1270.
  21. Poller M. S. Hemoglobin- and myoglobin-induced acute renal failure in rats: Role of iron in nephrotoxicity. Am. J. Physiol. 1988; 255: F438-F443.
  22. Gupta A., Malhotra H. S., Kumar L. et a!. Acute renal failure due leukemic infiltration of kidneys (see comments). J. Assoc. Physicians (India) 1990; 38 (4): 284-286.
  23. Haraldsdottir V., Haanen G., Jordans J. G. Chronic lymphocytic leukemia presenting as renal failure with lymphocytic infiltration of the kidneys. Neth. J. Med. 1992; 41 (1-2): 64- 67.
  24. Mills N. E., Goldenberg A. S., Liu D. et al. B-cell lymphoma presenting as infiltrative renal disease. Am. J. Kidney Dis. 1992; 19(1): 181-184.
  25. Saggi S.., Calandri C., Muhifelder T. et al. Renal failure due to leukemic infiltration in chronic lymphocytic leukemia. Neph- rol. Dial. Transplant. 1990; 5 (12): 1051-1052.
  26. Шелухин В. А., Мазуров В. И., Новик А. А. и др. Специфическое поражение почек при злокачественных неход- жкинских лимфомах. В кн.: Тезисы докладов I съезда нефрологов России, 11 - 13 окт. 1994. Казань; 1994. 91.
  27. Bunchman Т. Е., Gale G. В., O'Connor D. M. et al. Renal biopsy diagnosis of acute lymphocytic leukemia. Clin. Nephrol. 1992; 38 (3): 142-144.
  28. Clark A. D., Shelty A., Soutar R. Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Rev. 1999; 13 (2): 79-90.
  29. Тагиров И. С., ТЬгирова Д. И. К особенностям нефропатии при множественной миеломе. В кн.: Тезисы докладов 1 съезда нефрологов России, 11-13 окт. 1994. Казань; 1994. 87.
  30. Barret В. J. Contrast nephrotoxicity. J. Am. Soc. Nephrol. 1994; 5: 125-137.
  31. Catting H. O. Inappropriate secretion of ADH secondary to vincristine therapy. Am. J. Med. 1971; 51: 269.
  32. Cooper K., Bennett W. Nephrotoxicity of common drugs used in clinical practice. Arch. Intern. Med. 1987; 147: 1213-1218.
  33. Fillastre J. P., Moulin R., Jodin M. et al. Renal complication of anticancer chemotherapy. Pathol, et Biol. 1986; 34: 1013.
  34. Gruss E., Bernis C., Tomas J. F. et al. Acute renal failure in patiens following bone marrow transplantation: prevalence, risk factors and outcome. Am. J. Nephrol. 1995; 15: 473-479.
  35. Khalil M., Shin H. J., Tan A. et al. Macrophagelike vacuolated renal tubular cells in the urine of a male with osmotic nephrosis associated with intravenous immunoglobulin therapy. A case report. Acta Cytol. 2000; 44 (1): 86-90.
  36. Kremery V., Fischberger, Jocar M. Nephrotoxicity of aminoglycosides, polypeptides and cephalosporines in cancer patients. Chemotherapy 1991; 37 (4): 289-291.
  37. Kurschel E., Metz-Kurschel U., Niederle V. et al. Investigation on the subclinical and clinical nephrotoxicity of interferon alpha-2B in patients with myeloproliferative syndromes. Renal Failure 1991; 13 (2- 3): 87-93.
  38. Laidlaw S., Bainton R., Wilkie M., Makris M. Acute renal failure in acquired hemophilia following the use of high dose intravenous immunoglobulin. Hemophilia 1999; 5 (4): 270-272.
  39. Myers B. D. Cyclosporine nephrotoxicity. Kidney 1986; 30: 964.
  40. Rabb H., Gunasekaran H., Gunasekaran S., Saba S. R. Acute renal failure multiple myeloma precipitated by ACE inhibitors. Am. J. Kidney Dis. 1999; 33 (2): E5.
  41. Shah M., Jenis E. H., Mookerjee B. K. et al. Interferon-alphaassociated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy. Cancer 1998; 83 (9): 1938-1946.
  42. Shohaib S. Injection of diclofenac precipitating oliguric acute renal failure in a patient with kidney myeloma. Nephron 2000; 85 (1):96.
  43. Tanaka M., Kanamori H., Yamaji S. et al. Low-dose cytarabineinduced hepatic and renal dysfunction in patient with myelodysplastic syndrome. Anticancer Drugs 1999; 10 (3): 289-291.
  44. Badr K. F. Novel mediators of sepsis-associated renal failure. Semin. Nephrol. 1994; 14: 3-7.
  45. Tran D. D., Groeneveld A. B. J., van der Meulen J. et al. Age, chronic disease, sepsis, organ system failure, and mortality in a medical intensive care unit. Crit. Care Med. 1990; 18: 474-479.
  46. Ronco C., Bellomo R. Critical care nephrology. Dordrecht Boston, London; 1997.
  47. Goodnough L. Т., Monk T. G., Andriole G. L. Erythropoietin therapy. N. Engl. J. Med. 1997; 336: 935.
  48. Alvarez L., Puleo J., Balian J. A. Investigation of gastrointestinal bleeding in patients with renal disease. Am. J. Gastroenterol. 1993; 88: 33.
  49. Andrassy K., Ritz E. Uremia as a cause of bleeding. Am. J. Nephrol. 1985; 5: 313-319.
  50. Caen J. P., Rosa J. P. Platelet-vessel wall interaction: from the bedside to molecules. Thromb. Hemostas. 1995; 74 (1): 18- 24.
  51. Eberst M. E., Berkowitz L. R. Hemostasis in renal disease: pathophysiology and management. Am. J. Med. 1994; 96: 168-179.
  52. Meattem W. D., Hak L. J., Lamanna R. W. et al. Malnutrition, altered immune function and the risk of infection in maintenance hemodialysis. Am. J. Kidney Dis. 1982; 1: 106.
  53. Muscaritoli M., Conversano L. et al. Clinical and metabolic effects of different parenteral nutrition regiments in patients undergoing allogeneic bone marrow transplantation. Transplantation 1998; 66: 610-616.
  54. Pomposelli J. J., Flores E. A., Bistrian B. R. Role of biochemical mediators in clinical nutrition and surgical metabolism. J. Parenter. Enter. Nutr. 1988; 12: 212-218.
  55. Kao P. C., Clee G. G. Parathyreoid hormone-related peptide in plasma of patients with hypercalcemia and malignant lesions. Mayo Clin. Proc. 1990; 65 (suppl. 1): 1399-1407.
  56. Kaplan B. S., Herbert D., Morell R. E. Acute renal failure induced by hyperphosphatemia in acute lymphoblastic leukemia. Can. Med. Assoc. 1981; 124: 429-431.
  57. Goldstein D. J., Frederico С. В. The effect of urea kinetic modeling on the nutrition management of hemodialysis patients. J.Am. Diet. Assoc. 1987; 4: 474.
  58. Kosanovich J. M., Dumler F., Horst M. et al. Use of urea kinetics in the nutritional care of the acutelly ill patient. J. Parenter. Enter. Nutr. 1985; 9: 165.
  59. Schaefer R. M., Schaefer Z., Horl W. H. Mechanism for protein catabolism in ARF. Nephrol. Dial. Transplant. 1994; suppl. 3 : 44-47.
  60. Schapira D. V., Studnicki J., Bradham D. D. et al. Intensive care, survival and expence of treating critically ill cancer patients. J. A. M. A. 1993; 269 (6): 783-786.
  61. Wilmore D. W. Catabolic illness: strategies for enhancing recovery. N. Engl. J. Med. 1992; 325: 695-702.
  62. Benezet S., Chatelut E. et al. Inefficacy of exchangetransfusion in case of a methotrexate poisoning. Bull. Cancer 1997; 84 (8): 788-790.
  63. Bennett W. M. Adjustment of drug dosage in patients with renal insufficiency. In: Kelley W. M., ed. Textbook of internal medicine. New York; Lippincott; 1991. 763.
  64. Conger J. D. Drug therapy in acute renal failure. In: Lazarus J. M., Brenner В. М., eds. Acute renal failure. 3rd ed. New York: Churchill Livingston; 1993. 527-552.
  65. Dodwell D. J. Cytotoxic drugs: the search for dose response. Lancet 1993; 341 (6): 614-616.
  66. Bellomo R., Ronco С. Acute renal failure in the intensive care unit: adequacy of dialysis and the case for continuous therapies. Nephrol. Dial. Transplant. 1996; 11: 424-428.
  67. Harris D. Editorial: Acute renal replacement: Which treatment is best? Aust. N. Z. J. Med. 1990; 20: 197-200.
  68. Kjellstrand С. M., Pru С. E., Jahnke W. R. et al. Acute renal failure. In: Drukker W., Parsons F. M., Mather J. F., eds. Replacement of renal function by dialysis. Boston: Martinus Nijhoff Publ; 1983. 536.
  69. Conger J. D. Does hemodialysis delay recovery from acute renal failure? Semin. Dial. 1990; 3: 146-148.
  70. Hakim R. M., Wingard R. L., Parker R. A. Effects of the dialysis membrane in the treatment of patients with acute renal failure. N. Engl. J. Med. 1994; 331: 1338-1342.
  71. Schiffl H., Lang S. M., Konig A. et al. Biocompatible membranes in acute renal failure: prospective case-controlled study. Lancet 1994; 344: 570-572.
  72. Adler A. G., Ferran N.. Berlyn G. M. Effect of morganic phosphate on serum ionized calcium concentration in vitro: fa reassessment of the "trade-off hypothesis". Kidney Int. 1985; 28: 932.
  73. Heidland A., Wetzels E. Discussion: magnesium metabolism. Contrib. Nephrol. 1984: 38: 203.
  74. Palmer B. F. The effect of dialysate composition on systemic hemodinamics. Semin. Dial. 1992; 5: 54.
  75. Stewart S. К. The composition of dialysis fluid. In: Maher J. F., ed. Replacement of renal function bv dialysis. 3rd ed. Boston: Kluwer Academic Publishers; 1989. 199.
  76. De Broe M. E., De Backer W. A. Pathophysiology of hemodialysis associated hypoxemia. Adv. Nephrol. 1989; 18: 297.
  77. Davenport A., Will E. J., Davison A. M. Hyperlactatemia and metabolic acidosis during hemofiltration using lactate-buffered fluids. Nephron 1991; 59 (3): 461-465.
  78. Davenport A., Will E. J., Davison A. M. The prognostic use of a lactate infusion in patients with severe hepatorenal failure. Renal Failure 1991; 13 (2-3): 111-118.
  79. Bambauer R., Mestres P., Pirrung K. J. Frequency, therapy and prevention of infections associated with large bore catheters.ASAIO J. 1992; 38: 96-101.
  80. Bercoben M. S., Schwab S. J. Vascular access for hemodialysis.In: Nissenson A. R. Clinical dialysis. 3rd ed. Connecticut: Appleton & Lange; 1995: 26-45.
  81. Feldman H. I., Kobrin S., Wasserstain A. Hemodialysis vascular access morbidity. J. Am. Soc. Nephrol. 1996; 7: 523-535.
  82. Шулутко Е. М., Буланова Е. Л., Городецкий В. М. и др. Проблема сосудистого доступа в гематологической клинике. Пробл. гематол. 1995; 2: 6.
  83. Davenport A., Will E. J., Davison A. M. Comparison of the use of standard heparin and prostacyclin anticoagulation in spontaneous and pump-driven extracorporal circuits in patients with combined acute renal and hepatic failure. Nephron 1994; 66 (4): 431-437.
  84. Favre H., Martin P. Y., Stoermann С. Anticoagulation in continuous extracorporeal renal replacement therapy. Semin. Dial. 1996; 9: 112-118.
  85. Mehta R. L., Dobos G. J., Ward D. M. Anticoagulation in continuous renal replacement procedures. Ibid. 1992; 5: 61-66.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2003 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies